| BRD7 inhibits enhancer activity and expression of BIRC2 to suppress tumor growth and metastasis in nasopharyngeal carcinoma. | BRD7 inhibits enhancer activity and expression of BIRC2 to suppress tumor growth and metastasis in nasopharyngeal carcinoma.
Li M, Wei Y, Liu Y, Wei J, Zhou X, Duan Y, Chen S, Xue C, Zhan Y, Zheng L, Deng H, Tang F, Fan S, Xiong W, Li G, Tan M, Zhou M., Free PMC Article | 02/16/2023 |
| Prognostic Significance of the BIRC2-BIRC3 Gene Signature in Head and Neck Squamous Cell Carcinoma. | Prognostic Significance of the BIRC2-BIRC3 Gene Signature in Head and Neck Squamous Cell Carcinoma.
Lee MK, Noh JK, Woo SR, Kong M, Lee YC, Lee JW, Ko SG, Eun YG., Free PMC Article | 09/3/2022 |
| Cytoplasmic and Nuclear Functions of cIAP1. | Cytoplasmic and Nuclear Functions of cIAP1.
Zadoroznyj A, Dubrez L., Free PMC Article | 04/23/2022 |
| BIRC2-BIRC3 amplification: a potentially druggable feature of a subset of head and neck cancers in patients with Fanconi anemia. | BIRC2-BIRC3 amplification: a potentially druggable feature of a subset of head and neck cancers in patients with Fanconi anemia.
Roohollahi K, de Jong Y, Pai G, Zaini MA, de Lint K, Sie D, Rooimans MA, Rockx D, Hoskins EE, Ameziane N, Wolthuis R, Joenje H, Wells SI, Dorsman J., Free PMC Article | 02/26/2022 |
| Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer. | Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer.
Crawford N, Stott KJ, Sessler T, McCann C, McDaid W, Lees A, Latimer C, Fox JP, Munck JM, Smyth T, Shah A, Martins V, Lawler M, Dunne PD, Kerr EM, McDade SS, Coyle VM, Longley DB., Free PMC Article | 02/12/2022 |
| Inhibition of BIRC2 Sensitizes alpha7-HPV-Related Cervical Squamous Cell Carcinoma to Chemotherapy. | Inhibition of BIRC2 Sensitizes α7-HPV-Related Cervical Squamous Cell Carcinoma to Chemotherapy.
Lin CY, Wang CC, Wu RC, Yang LY, Chang CB, Pan YB, Chao A, Lai CH., Free PMC Article | 01/1/2022 |
| Development of a protein signature to enable clinical positioning of IAP inhibitors in colorectal cancer. | Development of a protein signature to enable clinical positioning of IAP inhibitors in colorectal cancer.
McCann C, Matveeva A, McAllister K, Van Schaeybroeck S, Sessler T, Fichtner M, Carberry S, Rehm M, Prehn JHM, Longley DB. | 10/2/2021 |
| BIRC2 Expression Impairs Anti-Cancer Immunity and Immunotherapy Efficacy. | BIRC2 Expression Impairs Anti-Cancer Immunity and Immunotherapy Efficacy.
Samanta D, Huang TY, Shah R, Yang Y, Pan F, Semenza GL. | 06/5/2021 |
| Stabilization of C-terminal binding protein 2 by cellular inhibitor of apoptosis protein 1 via BIR domains without E3 ligase activity. | Stabilization of C-terminal binding protein 2 by cellular inhibitor of apoptosis protein 1 via BIR domains without E3 ligase activity.
Seo TW, Lee YT, Lee JS, Yoo SJ. | 02/27/2021 |
| Future Therapeutic Directions for Smac-Mimetics. | Future Therapeutic Directions for Smac-Mimetics.
Morrish E, Brumatti G, Silke J., Free PMC Article | 02/27/2021 |
| A20 Promotes Ripoptosome Formation and TNF-Induced Apoptosis via cIAPs Regulation and NIK Stabilization in Keratinocytes. | A20 Promotes Ripoptosome Formation and TNF-Induced Apoptosis via cIAPs Regulation and NIK Stabilization in Keratinocytes.
Feoktistova M, Makarov R, Brenji S, Schneider AT, Hooiveld GJ, Luedde T, Leverkus M, Yazdi AS, Panayotova-Dimitrova D., Free PMC Article | 02/13/2021 |
| Increased Expression of BIRC2, BIRC3, and BIRC5 from the IAP Family in Mesenchymal Stem Cells of the Umbilical Cord Wharton's Jelly (WJSC) in Younger Women Giving Birth Naturally. | Increased Expression of BIRC2, BIRC3, and BIRC5 from the IAP Family in Mesenchymal Stem Cells of the Umbilical Cord Wharton's Jelly (WJSC) in Younger Women Giving Birth Naturally.
Gil-Kulik P, Świstowska M, Kondracka A, Chomik P, Krzyżanowski A, Kwaśniewska A, Rahnama M, Kocki J., Free PMC Article | 01/9/2021 |
| MiR-5195-3p inhibits the proliferation of glioma cells by targeting BIRC2. | MiR-5195-3p inhibits the proliferation of glioma cells by targeting BIRC2.
Yang J, Yan DM, Xhu LX, Si DM, Liang QH. | 01/2/2021 |
| PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1. | PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1.
Guo H, Treude F, Krämer OH, Lüscher B, Hartkamp J., Free PMC Article | 10/24/2020 |
| SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway. | SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway.
Ding J, Qin D, Zhang Y, Li Q, Li Y, Li J., Free PMC Article | 10/10/2020 |
| Tumor necrosis factorrelated apoptosisinducing ligand as a therapeutic option in urothelial cancer cells with acquired resistance against firstline chemotherapy. | Tumor necrosis factor‑related apoptosis‑inducing ligand as a therapeutic option in urothelial cancer cells with acquired resistance against first‑line chemotherapy.
Vallo S, Stege H, Berg M, Michaelis M, Winkelmann R, Rothweiler F, Cinatl J Jr. | 09/19/2020 |
| Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV(-) and HPV(+) Head and Neck Cancers to TNFalpha, TRAIL, and Radiation Therapy. | Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV(-) and HPV(+) Head and Neck Cancers to TNFα, TRAIL, and Radiation Therapy.
Xiao R, An Y, Ye W, Derakhshan A, Cheng H, Yang X, Allen C, Chen Z, Schmitt NC, Van Waes C., Free PMC Article | 09/12/2020 |
| cIAP1 is an oncological protein abundant in gallbladder cancer tissues, which enhances proliferation and immigration and blocks TNF-alpha from apoptosis through NF-kappaB pathway in vitro. | cIAP1 promotes proliferation and migration and prevents apoptosis in gallbladder cancer in vitro.
Su W, Jiang X, Chen M, Huang M, Tang N, Wang X, Li X, She F, Chen Y., Free PMC Article | 04/18/2020 |
| High cIAP1 expression is correlated with Head and Neck Cancer. | Co-expression of XIAP and CIAP1 Play Synergistic Effect on Patient's Prognosis in Head and Neck Cancer.
Yang XH, Liu L, Hu YJ, Zhang P, Hu QG. | 01/4/2020 |
| cIAP1 regulates the EGFR/Snai2 axis in triple-negative breast cancer cells | cIAP1 regulates the EGFR/Snai2 axis in triple-negative breast cancer cells.
Majorini MT, Manenti G, Mano M, De Cecco L, Conti A, Pinciroli P, Fontanella E, Tagliabue E, Chiodoni C, Colombo MP, Delia D, Lecis D., Free PMC Article | 10/19/2019 |
| Pfn2 levels, regulated by cIAP1, affected intracellular levels of reactive oxygen species. | Ubiquitin-proteasome dependent regulation of Profilin2 (Pfn2) by a cellular inhibitor of apoptotic protein 1 (cIAP1).
Jeong DH, Choi YN, Seo TW, Lee JS, Yoo SJ. | 05/25/2019 |
| results disclose the mechanism by which cIAP1 RING dimer activates UbcH5B approximately Ub and indicate that noncovalent Ubiquitin (Ub) binding further stabilizes the cIAP1-UbcH5B approximately Ub complex in the active conformation to stimulate Ub transfer | Structural insights into non-covalent ubiquitin activation of the cIAP1-UbcH5B∼ubiquitin complex.
Patel A, Sibbet GJ, Huang DT., Free PMC Article | 05/4/2019 |
| Our results provide the first evidence for a mediator function of cIAP1 and collaborative activity of cIAP1 and CHIP, suggesting that maintaining balanced levels of these E3 ligases might be beneficial for normal cell growth. | A novel function of cIAP1 as a mediator of CHIP-driven eIF4E regulation.
Seo TW, Lee JS, Choi YN, Jeong DH, Lee SK, Yoo SJ., Free PMC Article | 04/20/2019 |
| BIRC2 is a target gene for the E2F1 Transcription factor and is required for chromatin binding. | E2F1 binds to the peptide-binding groove within the BIR3 domain of cIAP1 and requires cIAP1 for chromatin binding.
Allègre J, Cartier J, Glorian V, Droin N, Dumetier B, Kayaci C, Berthelet J, Gemble S, Vuillier C, Maillet L, Garrido C, Dubrez L., Free PMC Article | 04/13/2019 |
| study provides an interesting example using chemical biological approaches for determining distinct biological consequences from inhibiting vs. activating an E3 ubiquitin ligase and suggests a potential broad therapeutic strategy for targeting c-MYC in cancer treatment by pharmacologically modulating cIAP1 E3 ligase activity. | Inhibition of cIAP1 as a strategy for targeting c-MYC-driven oncogenic activity.
Li H, Fang Y, Niu C, Cao H, Mi T, Zhu H, Yuan J, Zhu J., Free PMC Article | 10/20/2018 |